Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia (Q48085869)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 April 2014

Language	Label	Description	Also known as
English	Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia	scientific article published on 16 April 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

0 references

1 reference

based on heuristic

inferred from title

author name string

Stephen P Mulligan

1

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Karin Karlsson

2

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Mats Strömberg

3

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Viggo Jønsson

4

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Devinder Gill

5

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Jens Hammerström

6

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Mark Hertzberg

7

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Roger McLennan

8

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Bertil Uggla

9

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

John Norman

10

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Jonas Wallvik

11

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Gunnel Sundström

12

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Hemming Johansson

13

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Yvonne Brandberg

14

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Jan Liliemark

15

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Gunnar Juliusson

16

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Scandinavian and Australasian Leukaemia Lymphoma Groups (Allg)

17

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

publication date

16 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

55

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

12

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

2769-2777

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Chronic lymphocytic leukaemia: current first-line therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893306

21 January 2018

Identifiers

10.3109/10428194.2014.893306

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

release_wcegpmjbhndofhiy7p6cdlj7vq

1 reference

https://api.fatcat.wiki/v0/release/wcegpmjbhndofhiy7p6cdlj7vq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/24524339

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48085869&oldid=2184389692"